#214168

Vega Therapeutics Receives FDA Orphan Drug Designation for VGA039 for the Treatment of von Willebrand Disease

SOUTH SAN FRANCISCO, CA, May 23, 2023 – Vega Therapeutics, Inc., a clinical stage biotechnology company developing novel therapies...

By |2023-05-22T22:49:30-04:00May 23, 2023|Press Release|0 Comments
Read More

Vega Therapeutics Initiates Clinical Trial Program for VGA039, a First-in-Class Antibody Therapy for von Willebrand Disease

Phase 1 Clinical Trial Advances with First Subject Dosed in the E.U. and IND Accepted in the U.S...

By |2023-05-05T09:50:48-04:00April 6, 2023|Press Release|0 Comments
Read More

Electra Therapeutics to Highlight ELA026 in Three Presentations at the American Society of Hematology (ASH) 2022 Annual Meeting

By |2022-12-05T18:43:44-05:00November 3, 2022|Press Release|0 Comments
Read More

Electra Therapeutics announces $84 million Series B financing and unveils its novel SIRP targeted therapies for immunological diseases and cancer

Company’s first-in-class approach to targeting of signal regulatory proteins (SIRP) [...]

By |2022-12-05T18:44:13-05:00February 16, 2022|Press Release|0 Comments
Read More

Star Therapeutics emerges from stealth mode raising $100M in financing since inception to be an innovation engine for rare disease therapies

Drug discovery approach uncovers novel biology for treatments that can [...]

By |2022-12-05T18:39:45-05:00February 16, 2022|Press Release|0 Comments
Read More

© 2022 STAR Therapeutics Inc.

THANK YOU

We look forward to connecting with you